Mpox vaccine trial for infants: could a Half-Dose protect just as well?

NCT ID NCT06844487

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Jean-Pierre Van geertruyden Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 study is testing the MVA-BN mpox vaccine in 344 infants and children aged 4 to 24 months in the Democratic Republic of the Congo, a region heavily affected by mpox. Researchers are comparing a standard dose to a half-dose to see if the lower dose is still effective and causes fewer side effects. The goal is to find the best way to protect young children from mpox.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MVA-BN vaccine (Modified Vaccinia Ankara-Bavarian Nordic)
What this could lead to: If successful, this could show that a lower dose of the mpox vaccine is safe and effective for infants and young children, helping protect a high-risk population.
What could go wrong: This is an early-stage trial in a specific region, and results may not apply to other populations. The half-dose might not trigger a strong enough immune response, and side effects in infants are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDREN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

smallpox monkeypox prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHILDREN IMMUNOGENICITY INFANTS MPOX (MONKEYPOX) SAFETY VACCINATION

Contacts and locations

Locations

Boende Hôpital Général de Référence, Boende

Boende, La Tshuapa, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.